Opendata, web and dolomites

AMPK-DIAB SIGNED

A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AMPK-DIAB project word cloud

Explore the words cloud of the AMPK-DIAB project. It provides you a very rough idea of what is the project "AMPK-DIAB" about.

calf    fasting    heart    90    world    free    insulin    kidney    1980    balance    economies    organism    disease    line    fill    none    class    blindness    quadrupled    cell    company    recommended    nerve    add    energy    regimen    individuals    molecule    validation    activator    strategically    2014    obesity    iib    activated    proof    t2d    outlicensing    metformin    rate    approx    attack    patients    first    iia    protein    hyperaemic    ampk    candidate    peripheral    commercialize    gap    drugs    o304    living    epidemic    million    amputations    reduces    middle    hallmark    insufficient    efficient    primary    arterial    validated    denoted    obese    clinical    regulator    diabetes    resistance    adults    small    treatments    stable    blood    data    people    glucose    t2    amp    treatment    422    life    close    muscle    lifestyle    becomes    diagnosed    single    damage    aged    clinicians    plasma    complications    108    betagenon    complication    drug    performing    date    cardiovascular    delivering    validate    threatens    diabetics    market    kinase    stroke   

Project "AMPK-DIAB" data sheet

The following table provides information about the project.

Coordinator
BETAGENON AB 

Organization address
address: TVISTEVAGEN 48C
city: UMEA
postcode: 907 36
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://betagenon.se/
 Total cost 2˙604˙625 €
 EC max contribution 1˙823˙237 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2018-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BETAGENON AB SE (UMEA) coordinator 1˙823˙237.00

Map

 Project objective

This project aims to close the gap to the market for a small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novel first-in-class drug for the treatment of type 2 diabetes (T2D) and associated cardiovascular complications, including heart failure and peripheral arterial disease.

The number of adults around the world with diabetes quadrupled from 108 million in 1980 to 422 million in 2014. About 90% of these people have type 2 diabetes — a major cause of kidney failure, blindness, nerve damage, amputations, heart attack and stroke. It is estimated that only approx. 10 % of T2 diabetics reach the goal of living a complication free life. Today, patients diagnosed with T2D are recommended a change in lifestyle and the drug Metformin is the first line of treatment. When Metformin becomes insufficient, a number of add-on treatments are used, including insulin. None of the existing drugs, however, reduces insulin resistance - a primary cause of obesity-induced T2D.

Betagenon has developed and pre-validated the first candidate AMPK activator drug in T2 diabetics, a key regulator of energy balance, both on a single cell level and the whole organism level. Phase I clinical data show that O304 reduces fasting plasma glucose, the hallmark of T2D, in patients with T2D on stable metformin treatment, and increases the rate of hyperaemic blood in calf muscle in middle aged obese individuals. The project is strategically focused on performing a Phase IIa proof-of-concept validation of O304. This will enable Betagenon to commercialize the product through outlicensing to a Phase IIb and Phase III validation partner.

Diabetes is an epidemic that threatens the economies of all EU member states. The project addresses this challenge by delivering a novel drug treatment regimen to clinicians and their patients. O304 will fill the knowledge gap on the EU level, as to date no company has been able to pre-validate an efficient small molecule AMPK activator.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AMPK-DIAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AMPK-DIAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More